In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
INDICATIONS:Pediatric patients with molybdenum cofactor deficiency Type A
HALF-LIFE:1.2–1.7 hours
FDA APPROVAL DATE:02/26/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH: None known
PREGNANCY: No available data on fosdenopterin use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Potential for photosensitivity: Advise patients/caregivers to avoid patient exposure to sunlight, and to have the patient wear sunscreen, protective clothing, and sunglasses when exposed to the sun. If photosensitivity occurs, advise caregivers/patients to seek medical attention immediately and consider a dermatological evaluation.
The clinical trial data annotated for fosdenopterin refer to 9 treated patients.
Please login to view the rest of this drug profile.